Hemochromatosis Type 3 — Clinical Trials

MONDO:00114172 activeLast updated: Mar 20, 2026, 1:51 PM

Trial Landscape

Hemochromatosis Type 3 has an emerging clinical trial program, driven by drug treatment and procedure.

Recruiting

Active Trials

By Approach

Drug Treatment1

Procedure1

1 additional trials involve behavioral, dietary, diagnostic, or observational approaches.

By Phase

Phase 1

Phase 2

Sponsor Types

NIH1Industry1

Top Sponsors

Bond Biosciences

Trial Locations

Australia1 trial

United States1 trial

Trials often recruit across multiple countries, so totals exceed the trial count.

2 Trials

Phase 1Not Yet Recruiting

NCT07371793

A Study to Evaluate BBI-001 in Healthy Volunteers and in Patients With Hereditary Hemochromatosis

Sponsor:Bond Biosciences

AustraliaStarted: Mar 2026Est. completion: Feb 2027Updated: Jan 2026

Phase 2Active, Not Recruiting

NCT00007150

Treatment of Hemochromatosis

Sponsor:National Institutes of Health Clinical Center (CC)

United StatesStarted: Jan 2001Est. completion: Dec 2026Updated: Mar 2026

Stay informed about clinical trials for Hemochromatosis Type 3.

Follow this disease to get updates when trials open, close, or change status.

Follow This Disease — Free

Already have an account? Sign in to manage your watchlists.

Data sourced from ClinicalTrials.gov via Kisho's automated pipeline. Trials refreshed every 4 hours for monitored diseases.

Last sync: March 20, 2026 at 1:51 PM